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Abstract
Background: Thrombolytic therapy with tissue plasminogen activator (tPA) benefits patients with acute ischemic
stroke. However, tPA increases the risk for intracerebral bleeding and enhances post-ischemic neuronal injury if
administered 3-4 hours after stroke. Therefore, combination therapies with tPA and neuroprotective agents have
been considered to increase tPA’s therapeutic window and reduce toxicity. The anticoagulant factor protein S (PS)
protects neurons from hypoxic/ischemic injury. PS also inhibits N-methyl-D-aspartate (NMDA) excitotoxicity by
phosphorylating Bad and Mdm2 which blocks the downstream steps in the intrinsic apoptotic cascade. To test
whether PS can protect neurons from tPA toxicity we studied its effects on tPA/NMDA combined injury which in
contrast to NMDA alone kills neurons by activating the extrinsic apoptotic pathway. Neither Bad nor Mdm2 which
are PS’s targets and control the intrinsic apoptotic pathway can influence the extrinsic cascade. Thus, based on
published data one cannot predict whether PS can protect neurons from tPA/NMDA injury by blocking the
extrinsic pathway. Neurons express all three TAM (Tyro3, Axl, Mer) receptors that can potentially interact with PS.
Therefore, we studied whether PS can activate TAM receptors during a tPA/NMDA insult.
Results: We show that PS protects neurons from tPA/NMDA-induced apoptosis by suppressing Fas-ligand (FasL)
production and FasL-dependent caspase-8 activation within the extrinsic apoptotic pathway. By transducing
neurons with adenoviral vectors expressing the kinase-deficient Akt mutant Akt
K179A and a triple FKHRL1 Akt
phosphorylation site mutant (FKHRL1-TM), we show that Akt activation and Akt-mediated phosphorylation of
FKHRL1, a member of the Forkhead family of transcription factors, are critical for FasL down-regulation and
caspase-8 inhibition. Using cultured neurons from Tyro3, Axl and Mer mutants, we show that Tyro3, but not Axl
and Mer, mediates phosphorylation of FHKRL1 that is required for PS-mediated neuronal protection after tPA/
NMDA-induced injury.
Conclusions: PS blocks the extrinsic apoptotic cascade through a novel mechanism mediated by Tyro3-dependent
FKHRL1 phosphorylation which inhibits FasL-dependent caspase-8 activation and can control tPA-induced
neurotoxicity associated with pathologic activation of NMDA receptors. The present findings should encourage
future studies in animal stroke models to determine whether PS can increase the therapeutic window of tPA by
reducing its post-ischemic neuronal toxicity.
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Thrombolytic therapy for acute ischemic stroke with a
recombinant tissue plasminogen activator (tPA) has clear
benefits if administered within a relatively narrow thera-
peutic window [1-3]. However, studies using animal mod-
els of stroke have indicated that tPA may exert serious
side effects in the ischemic brain which include blood-
brain barrier (BBB) breakdown [4-6] frequently resulting
in intracerebral bleeding if systemic tPA is administered 3-
4 h after stroke [7,8]. Moreover, a recent study using a
model of angiographically documented recanalization of
the rabbit middle cerebral artery occlusion has indicated
that tPA produces bleeding at all doses in proportion to
its thrombolytic potential [9]. These side effects limit use
of tPA therapy in humans with stroke [10,11].
Studies using a transient ischemia stroke models have
demonstrated direct post-ischemic neuronal toxicity of
tPA [12-14]. It has been also shown that tPA enhances
neuronal injury in the presence of N-methyl-D-aspartate
(NMDA) [15-18]. The exact mechanism(s) how tPA
interacts with the NMDA receptors (NMDARs) has,
however, been debated. Never-the-less most investiga-
tors agree that pathologic activation of NMDARs contri-
butes to neuronal death after acute excitotoxic trauma
such as brain ischemia [19,20]. It has been reported that
tPA enhances the neurotoxic effects of NMDA down-
stream to NMDARs by shifting the NMDA-induced
neuronal injury from the intrinsic to the extrinsic apop-
totic pathway [14]. Therefore, potential combination
therapies with tPA and neuroprotective agents hold
potential to increase the therapeutic window of tPA and
reduce its toxic effects in brain associated with patholo-
gic activation of NMDARs.
Protein S (PS) is a vitamin K-dependent anticoagulant
plasma glycoprotein with multiple biologic functions
[21]. Independent of its anticoagulant activity, PS exerts
direct cellular effects [22-24]. In the central nervous sys-
tem, PS is neuroprotective after a transient brain ische-
mia and also protects cultured neurons from hypoxia/
glucose deprivation followed by reoxygenation [25]. PS
enhances the BBB integrity after an ischemic insult as
shown in a model of human BBB endothelial mono-
layers in vitro and after a transient ischemia in mice in
vivo by acting on the TAM (Tyro3, Axl, Mer) receptor
tyrosine kinase Tyro3 [26].
Recently, we have demonstrated that PS protects neu-
rons from NMDA-induced excitotoxic injury by phos-
phorylating Bad and Mdm2 which in turn blocks the
downstream steps in the intrinsic apoptotic cascade
[27]. To test whether PS can protect neurons from tPA
toxicity we employed a model of tPA and NMDA
c o m b i n e di n j u r y[ 1 4 ] .I nc o n t r a s tt oN M D Aa l o n e ,a
simultaneous exposure of neurons to tPA and NMDA
kills neurons by activating the extrinsic apoptotic
pathway [14]. Bad [28,29] and Mdm2 [30,31] which con-
trol the intrinsic apoptotic cascade and p53/Bax proa-
poptotic pathway, respectively, are both targets of PS
[27], but neither can influence the extrinsic cascade.
Thus, based on the published work one cannot predict
whether PS will protect neurons from tPA/NMDA
injury by blocking the extrinsic pathway. Neurons
express all three TAM receptors, i.e., Tyro3, Axl and
Mer [32] Tyro3 and Mer were both shown to interact
with PS on different cells types during physiologic and/
or pathologic conditions [33-35]. Moreover, triple TAM
mutants develop neuronal apoptosis [36] and PS null
mice develop neuronal necrosis [37,38]. All these studies
suggest that interactions between different TAM recep-
tors and PS might be important for neuronal survival.
Therefore, we also studied whether PS can activate
TAM receptors during a tPA/NMDA insult.
Results
PS protects mouse cortical neurons from tPA/NMDA-
mediated injury
Mouse recombinant PS dose-dependently enhanced cell
survival (Figure 1A) and reduced by > 75% the number
of TUNEL-positive cells (Figure 1B-C) in 14-day old
cultures of mouse cortical neurons treated with tPA and
NMDA, as described in the Methods and previously
reported [14,15]. Because tPA/NMDA exposure has
been shown to trigger caspase-8-dependent cell death
[14], we explored whether PS attenuates tPA/NMDA-
induced toxicity by blocking the extrinsic apoptotic
pathway. Initial experiments showed that treatment with
caspase-8 and caspase-3 inhibitors (z-IETD-fmk, Ac-
DEVD-CHO), but not caspase-9 inhibitor (z-LEHD-
fmk), enhanced cell survival (Figure 1D), confirming
that tPA/NMDA-induced neuronal cell death is caspase-
8-dependent and that caspase-8 is upstream to caspase-
3, as reported [14]. Consistent with these results,
activation of both caspase-8 and caspase-3 in tPA/
NMDA-treated neurons was suppressed by the caspase-
8 inhibitor z-IETD-fmk, but not by a caspase-9 inhibitor
(Figure 1E-F). Treatment with PS (100 nM) blocked the
tPA/NMDA-mediated activation of both caspase-8 and
caspase-3. In these studies PS was added at concentra-
tion of 100 nM because the maximal protection with
murine PS in the present model has been achieved with
100 nM (Figure 1A).
In the extrinsic cell death pathway, activation of
caspase-8 is coupled to activation of death receptors by
proteins such as FasL [39]. Indeed, tPA/NMDA treat-
ment increased FasL expression (Figure 1G). Moreover,
addition of an anti-FasL neutralizing antibody at the
time of tPA/NMDA exposure prevented activation of
caspase-8 (Figure 1H). tPA/NMDA exposure failed to
elicit an increase in FasL expression in cells treated with
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Figure 1 PS protects mouse cortical neurons from tPA/NMDA-induced injury. (A) Dose-dependent neuroprotective effects of PS (12.5-200
nM) in a 14-day old neuronal cultures 24 h after tPA/NMDA treatment. Cell survival was quantified with a WST assay. (B) Representative
fluorescent-TUNEL (green)/Hoechst (blue) staining in mouse cortical neurons 24 h after tPA/NMDA treatment in the presence or absence of PS.
(C) The number of apoptotic TUNEL-positive cells quantified as described in the Methods in the presence of NMDA with and without tPA or PS.
(D) Survival of mouse cortical neurons 24 h after a combined tPA/NMDA treatment with and without PS, caspase-9 inhibitor (z-LEHD-fmk 5 μM),
caspase-8 inhibitor (z-IETD-fmk, 50 μM), or caspase-3 inhibitor (Ac-DEVD-CHO, 50 μM). (E) Caspase-8 activity in mouse cortical neurons 8 h after
tPA/NMDA exposure in the presence or absence of PS and a caspase-8 inhibitor (z-IETD-fmk; 50 μM). (F) Caspase-3 activity in mouse cortical
neurons 12 h after tPA/NMDA in the presence or absence of PS, caspase-9 inhibitor (z-LEHD-fmk 5 μM), caspase-8 inhibitor (z-IETD-fmk, 50 μM),
or caspase-3 inhibitor (Ac-DEVD-CHO, 50 μM). (G) Western blots for FasL in whole-cell extracts from mouse cortical neurons 6 h after tPA/NMDA
in the presence or absence of PS. Intensity of FasL signal was measured by scanning densitometry and normalized to b-actin. (H) Caspase-8
activity in mouse cortical neurons 8 h after tPA/NMDA in the presence of anti-FasL antibody (a-FasL; 10 μg/ml). Anti-FasL antibody was added
simultaneously with tPA-NMDA. Caspase inhibitors were applied 1 h prior to tPA/NMDA treatment. In all studies murine PS was used at 100 nM,
unless specified differently, and was added simultaneously with tPA (20 μg/ml) and NMDA (25 μM). Mean ± SEM, n = 3 independent cultures in
triplicate. *p < 0.05 compared with values in the absence of PS. NS, non-significant.
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Page 3 of 12PS (Figure 1G) suggesting that this may be the mechan-
ism by which PS prevents caspase-8 activation. Treat-
ment with tPA alone and PS alone did not affect the
number of TUNEL-positive cells, cell survival, caspase-8
and caspase-3 activities, and FasL production (Figure
1C-G). In this model, treatment with NMDA alone
caused less severe neuronal injury compared to tPA/
NMDA combination (Figure 1C-D) and did not affect
caspase-8 activity (Figure 1E), consistent with a previous
report [14].
PS neuroprotection requires activation of Akt signaling
PS requires activation of the phosphatidylinositol
3-kinase (PI3K)/Akt survival pathway as an upstream
signaling event to prevent NMDA-mediated neuronal
injury [27]. Thus, we tested whether the ability of PS to
protect neurons from tPA/NMDA-mediated injury also
requires PI3K/Akt activation as an initial step mediating
the observed neuronal protection. PS treatment stimu-
lated phosphorylation of Akt on Ser473 [40] in neurons
after tPA/NMDA challenge (Figure 2A-B). Because
phosphorylation levels of Akt may not entirely reflect its
protein kinase activity, we performed an immune com-
plex kinase assay using glycogen synthase kinase 3
(GSK3) as the Akt substrate [41]. Results from these
experiments confirmed that PS treatment stimulates Akt
kinase activity (Figure 2C-D). LY294002, a PI3K inhibi-
tor, blocked PS-mediated phosphorylation of Akt (Figure
2A-B) and neuronal protection (Figure 2E) after tPA/
NMDA exposure. This data suggests that PS’s neuropro-
tective effects requires an initial activation of the PI3K/
Akt pathway.
Activated Akt promotes cell survival in the extrinsic
apoptotic pathway by phosphorylating and inactivating
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Figure 2 PS protects tPA/NMDA-treated neurons via activation of PI3K/Akt signaling. (A) Western blots for pAkt (Ser473) and total Akt in
whole-cell extracts from mouse cortical neurons 2 h after tPA/NMDA exposure in the presence or absence of PS and LY294002 (50 μM). (B)
Intensity of pAkt signal was measured by scanning densitometry and normalized to total Akt. (C) Akt activity was determined 2 h after tPA/
NMDA exposure in the presence or absence of PS using an immune-complex kinase assay with GSK3 as the substrate. (D) Intensity of the pGSK3
signal was normalized to b-actin. (E) Survival of mouse cortical neurons 24 h after tPA/NMDA exposure in the presence or absence of PS and
LY294002 (50 μM). LY294002 was added to the culture 1 h before tPA/NMDA treatment. In all studies, murine PS was used at 100 nM and was
added simultaneously with tPA/NMDA. Mean ± SEM, n = 3 independent cultures in triplicate. NS, non-significant.
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Page 4 of 12FKHRL1, a member of the Forkhead family of tran-
scription factors [42]. Phosphorylation of FKHRL1
results in its cytoplasmic retention, whereas depho-
sphorylated FKHRL1 translocates into the nucleus
where it stimulates transcription of its target genes
including FasL in the extrinsic apoptotic pathway
[40,42]. Thus, we determined the protein levels of
three members of the Forkhead family, FKHRL1,
FKHR and AFX [43-45] in nuclear fractions prepared
from tPA/NMDA-treated neurons. Nuclear levels
of FKHRL1, but not of FKHR and AFX1, were significantly
increased by tPA/NMDA challenge (Figure 3A-B).
PS treatment blocked the increase in nuclear FKHRL1
(Figure 3A-B), and this was accompanied by an increase in
the amount of FKHRL1 phosphorylated on Ser253 (a site
phosphorylated by Akt [42]) in whole cell lysates from
tPA/NMDA-treated neurons (Figure 3C). However, PS did
not affect the levels of nuclear FKHRL1 and phosphory-
lated FKHRL1 in neurons without tPA/NMDA challenge
(Figure 3A, C).
T oc o n f i r mw h e t h e rA k tp l a y sak e yr o l ei nP S -
mediated neuronal protection, mouse cortical neurons
were transduced with a recombinant adenovirus expres-
sing a kinase-deficient Akt mutant (Ad.Akt
K179A )[ 4 6 ]
along with GFP. The transduction efficiency was ~70%
as determined by GFP fluorescence (data not shown).
Figure 3D shows that mouse cortical neurons trans-
duced with Ad.Akt
K179A did not affect cell survival
within 48 h of transduction. Ad.Akt
K179A expression, but
not control Ad.GFP, abolished PS-stimulated phosphor-
ylation of FKHRL1 (Figure 3E), down-regulation of FasL
(Figure 3F), inhibition of caspase-8 (Figure 3G) and
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Figure 3 PS-mediated neuroprotection requires Akt phosphorylation of FKHRL1. (A) Western blots for FKHR, FKHRL1 and AFX in nuclear
fractions from mouse cortical neurons treated with tPA/NMDA for 4 h in the presence or absence of PS. (B) Signals for FKHR, FKHRL1 and AFX
were normalized to histone H1. (C) Western blots for pFKHRL1 in whole-cell extracts from mouse cortical neurons prepared 4 h after tPA/NMDA
treatment in the presence or absence of PS. Intensity of pFKHRL1 signal was measured by scanning densitometry and normalized to b-actin.
(D) Time-dependent survival (12-72 h) of neurons after transduction with Ad. Akt
K179A. Cell survival was quantified with a WST assay. (E) Western
blots for pFKHRL1 in whole-cell extracts prepared from neurons transduced with Ad.Akt
K179A or Ad.GFP and exposed for 4 h to tPA/NMDA in the
presence or absence of PS. Intensity of the pFKHRL1 signal was normalized to b-actin. (F) Western blots for FasL in whole-cell extracts from
neurons transduced with Ad.Akt
K179A or Ad.GFP and treated for 6 h with tPA/NMDA in the presence or absence of PS. Intensity of the FasL signal
was normalized to b-actin. (G) Caspase-8 activity in neurons transduced with Ad.Akt
K179A or Ad.GFP and exposed to tPA/NMDA for 8 h in the
presence or absence of PS. (H) Cell survival of neurons transduced with Ad.Akt
K179A or control Ad.GFP and exposed to tPA/NMDA for 24 h in the
presence or absence of PS. In all studies murine PS was used at 100 nM and was added simultaneously with tPA/NMDA. Mean ± SEM, n = 3
independent cultures in triplicate. NS, non-significant.
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Page 5 of 12neuronal protection (Figure 3H) in neurons exposed to
tPA/NMDA.
We then tested the importance of phosphorylation of
FKHRL1 in PS-mediated neuronal protection. Mouse
cortical neurons were transduced with recombinant ade-
novirus expressing a triple mutant of FKHRL1 (Ad.
FKHRL1-TM), which cannot be phosphorylated by Akt
[47]. The transduction efficiency was ~70% as assessed
by GFP fluorescence (data not shown). Figure 4A illus-
trates the level of expression of FKHRL1-TM in mouse
cortical neurons compared to endogenous FKHRL1 in
control neurons. Since neurons expressing FKHRL1-TM
may undergo apoptosis [48], we examined the viability
of neurons transduced with Ad.FKHRL1-TM.O u rd a t a
showed that mouse cortical neurons transduced with
Ad.FKHRL1-TM did not undergo spontaneous apoptosis
within 48 h of transduction, although they did show
about 35% decrease in survival at 72 h (Figure 4B).
Thus, in subsequent experiments we transduced neu-
rons with Ad.FKHRL1-TM 24 h before tPA/NMDA
treatment. Results from these experiments showed that
Ad.FKHRL1-TM expression abolishes PS-mediated
down-regulation of FasL (Figure 4C), inhibition of cas-
pase-8 (Figure 4D) and neuronal protection (Figure 4E),
suggesting that FKHRL1 is a critical downstream step in
the PS-mediated blockade of the extrinsic apoptotic
pathway.
Tyro3 mediates PS neuroprotection and FKHRL1
phosphorylation
Next, we tested the role of TAM receptors in PS pro-
tection of tPA/NMDA-treated neurons. Using cortical
neurons from Tyro3
-/-, Axl
-/- and Mer
-/- mice, we
found that PS protects neurons lacking Axl and Mer
from tPA/NMDA-mediated injury, but failed to protect
neurons lacking Tyro3 (Figure 5A). Consistent with a
model whereby PS acts through Tyro3, we found that
mouse PS stimulated tyrosine phosphorylation of
Tyro3 on mouse cortical neurons challenged by
tPA and NMDA (Figure 5B). However, PS failed to
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Figure 4 PS-mediated Akt phosphorylation of FKHRL1 suppresses FasL production and activation of caspase-8. (A) Expression of FKHRL1
and FKHRL1-TM (triple mutant) in mouse cortical neurons 24 h after adenoviral transduction determined by total FKHRL1 immunoblotting
analysis. (B) Time-dependent survival (12-72 h) of neurons after transduction with Ad.FKHRL1-TM. Cell survival was quantified with a WST assay.
(C) Western blots for FasL in whole-cell extracts from neurons transduced with Ad.FKHRL1-TM or control Ad.GFP and treated for 6 h with tPA/
NMDA in the presence or absence of PS. Intensity of the FasL signal was normalized to b-actin. (D) Caspase-8 activity in neurons transduced
with Ad.FKHRL1-TM or Ad.GFP and exposed to tPA/NMDA for 8 h in the presence or absence of PS. (E) Cell survival of neurons transduced with
Ad.FKHRL1-TM or Ad.GFP and exposed to tPA/NMDA for 24 h in the presence or absence of PS. In all studies murine PS was used at 100 nM and
was added simultaneously with tPA/NMDA. Mean ± SEM, n = 3 independent cultures in triplicate. NS, non-significant.
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Page 6 of 12activate Akt (Figure 5C) and phosphorylate FKHRL1
(Figure 5D) in tPA/NMDA-treated neurons from
Tyro3 null mice.
Discussion
It has been recently reported that PS phosphorylates
the TAM receptor Tyro3 in neurons which protects
NMDA-treated neurons from cell death by inhibiting
the intrinsic apoptotic cascade [27]. Specifically, it has
been shown that PS acts on Tyro3 which activates the
PI3K/Akt pathway in NMDA-treated neurons resulting
in phosphorylation of Bad and Mdm2 which in turn
increases the levels of antiapoptotic Bcl-2 and Bcl-XL
proteins and reduces the levels of proapoptotic p53
and Bax, respectively, thus inhibiting the intrinsic
apoptotic cascade initiated by NMDA [27]. However,
in the present model of a combined tPA/NMDA
injury, a simultaneous exposure to tPA and NMDA
activates the extrinsic apoptotic cascade but does not
affect or amplify the intrinsic apoptotic pathway, as we
reported [14]. Moreover, the established phosphoryla-
tion targets of PS in the intrinsic apoptotic cascade,
i.e., Bad [28,29] and Mdm2 [30,31] as shown by a pre-
vious study [27], do not influence the extrinsic
cascade.
T h ep r e s e n ts t u d ys h o w sf o rt h ef i r s tt i m et h a tP Sc a n
block the extrinsic apoptotic cascade and protect neurons
from a combined tPA/NMDA-mediated injury. We also
show that inhibition of the extrinsic apoptotic cascade by
PS requires Tyro3-mediated phosphorylation of FKHRL1
which in turn inhibits FasL production and FasL-depen-
dent caspase-8 activation in the extrinsic pathway. These
results suggest that PS may protect neurons from diver-
gent inducers of apoptosis acting through either intrinsic
or extrinsic pathways, similar as reported for activated
protein C [49]. By using Tyro3-, Axl- and Mer-deficient
neurons, the present study demonstrates that an initial
upstream event in PS-mediated protection against tPA/
NMDA combined injury requires Tyro3 and activation of
the PI3K/Akt anti-apoptotic signaling pathway as in an
NMDA alone-mediated neuronal injury [27]. However,
the present study in tPA/NMDA-treated neurons estab-
lishes the link between PS-mediated activation of Tyro3
and FKHRL1 phosphorylation which inactivates pro-
apoptotic FKHRL1 [42] and mediates PS’s beneficial
effects. Namely, dephosphorylated FKHRL1 can trigger
the extrinsic apoptotic cell death by promoting expres-
sion of FasL followed by FasL-dependent activation of
caspase-8 [40,42]. Our data using a triple Akt-phosphory-
lation site mutant of FKHRL1 (i.e., FKHRL1-TM) [47]
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ronal injury involving activation of the extrinsic cascade.
Moreover, our data shows that PS-mediated inactivation
of FKHRL1 suppresses tPA/NMDA-induced FasL up-
regulation which subsequently blocks caspase-8
activation.
The importance of the extrinsic apoptotic cascade for
tPA/NMDA-mediated toxicity is further supported by
observation that >80% of caspase-3 activation in tPA/
NMDA-treated neurons was blocked by a caspase-8
inhibitor, but not with a caspase-9 inhibitor, similar as
shown in a previous study [14]. Both pro-caspase-3 and
Bid, a proapoptotic promoter of cytochrome c release
[50], are substrates for caspase-8. However, it has been
shown that tPA/NMDA-induced apoptotic signaling
does not require amplification through the intrinsic
pathway via Bid [14] in contrast to ischemic neuronal
death in vivo [50,51]. Therefore, our results are consis-
tent with a model in which PS blocks FasL and FasL-
dependent activation of caspase-8 followed by inhibition
of caspase-3 activation resulting in protection of tPA/
NMDA-treated neurons.
In addition to the effects of a combined tPA/NMDA
injury on signaling pathways downstream to NMDARs,
as shown in the present and a previous study [14], it has
been also suggested that tPA may interact directly with
NMDARs. For example, it has been proposed that tPA
cleaves the NR1 subunit of NMDARs potentiating
NMDA-induced calcium influx and neurotoxicity
[15,17,52] or that NR2D-containing NMDARs mediate
tPA-induced neuronal excitotoxicity [16], but this has
not been confirmed by other groups [18]. It has been
reported that seizures induced by ethanol-withdrawal
are controlled by tPA through modulation of NR2B-
containing NMDARs [53]. Other studies have indicated
that tPA binding to the low-density lipoprotein receptor
related protein-1 (LRP1) is necessary for NMDARs acti-
vation [54] and upregulation of matrix metalloprotei-
nase-9 expression at the BBB [55] resulting in an
increased BBB permeability [4,56] which in turn may
lead to accumulation in brain of blood-derived neuro-
toxins and vascular-mediated neuronal injury [57], as
shown for example in pericyte-deficient mouse models
[58,59]. Whether PS can act directly on NMDARs or
LRP1 to attenuate the neurotoxic signaling during a
tPA/NMDA-mediated insult should be addressed by the
future studies.
Conclusions
Our data suggests that PS blocks the extrinsic apoptotic
cascade through Tyro3-dependent phosphorylation of
FKHRL1 which in turn inhibits FasL-dependent caspase-8
activation and controls tPA-induced neuronal toxicity
associated with pathologic activation of NMDA receptors.
These findings should encourage future preclinical studies
in different animal stroke models using different species
and different administration regimens of tPA and PS to
determine whether PS can increase the therapeutic win-
dow of tPA by reducing its risk for intracerebral bleeding
and/or post-ischemic neuronal toxicity.
Methods
Reagents
Full-length properly gamma-carboxylated mouse recom-
binant PS was prepared and characterized as we
reported [23]. NMDA was purchased from Sigma (St
Louis, MO, USA). Mouse recombinant tPA was pur-
chased from Molecular Innovations (Novi, MI, USA).
For western blot analysis the following antibodies were
used: polyclonal rabbit antibody against mouse Fas
Ligand (FasL; EMD4Biosciences, Gibbstown, NY, USA),
polyclonal rabbit antibody against mouse Akt (Cell Sig-
naling, Danvers, MA, USA), polyclonal rabbit antibody
against mouse pAkt (Cell Signaling), polyclonal rabbit
antibody against human FKHR which cross reacts with
mouse FKHR (Cell Signaling), polyclonal rabbit antibody
against human FoxO3a which cross reacts with mouse
FoxO3a (FKHRL1, Cell Signaling), polyclonal rabbit
antibody against human pFoxO3a which cross reacts
with mouse pFoxO3a (pFKHRL1, Cell Signaling), poly-
clonal rabbit antibody against human AFX which cross
reacts with mouse AFX (Cell Signaling), and polyclonal
sheep antibody against human histone 1, which cross
reacts with mouse histone 1 (United States Biological,
Swampscott, MA, USA). The inhibitory peptides, Ac-
DEVD-CHO (caspase-3), z-IETD-fmk (caspase-8) and z-
LEHD-fmk (caspase-9) were selected on the basis of
substrate specificity [14] and purchased from Sigma.
LY294002 was purchased from Cell Signaling. Anti-FasL
neutralizing antibody was selected as reported [60,61]
and purchased from BD Pharmingen (clone MFL3; San
Diego, CA, USA).
Transgenic mice
T A Mt r a n s g e n i cm i c e( Tyro3
-/-, Axl
-/-, Mer
-/-)w e r eo r i -
ginally on C57B16/129 background [62,36]. These mice
were backcrossed for 10 generations to attain the
C57B16 background and were generated by null-null
breeding. The C57B16 mice were used as wild type con-
trols for the TAM null mice, as reported [[63]; please
see also the Jackson Laboratory website http://jaxmice.
jax.org/strain/007937.html]. The breeding pairs were ori-
ginally provided by Dr. G. Lemke from the Salk Institute
for Biological Studies, La Jolla, CA.
Mouse neuronal cell cultures
Primary neuronal cultures were established as described
[49]. In brief, cerebral cortex was dissected from
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TAM null mice, treated with trypsin for 10 min at 37°C
and dissociated by trituration. Dissociated cell suspen-
sions were plated at 3.5 × 10
5 cells per well on 12-well
tissue culture plates or at 1.5 × 10
6 cells per well on 6-
well tissue culture plates coated with poly-L-lysine, in
serum-free Neurobasal medium plus B27 supplement
(Gibco, Rockville, MA, USA). The medium suppresses
glial growth to < 0.5% of the total cell population, as
demonstrated by immunocytochemistry for glial fibrilary
acidic protein [64,65]. Cultures were allowed to mature
for 14 days in vitro before treatment as reported [14].
Medium was replaced every 3 days.
tPA/NMDA injury model
For induction of neuronal apoptosis, neuronal cultures
were treated with mouse recombinant tPA (20 μg/ml)
and 25 μMN M D A / 5μM glycine in serum-free Neuro-
basal medium plus B27 supplement for 2-24 h as
reported [14,15].
Detection of apoptosis
Apoptotic cells were visualized by in situ terminal deox-
ynucleotidyl transferase-mediated digoxigenin-dUTP
nick-end labeling (TUNEL) assay according to manufac-
turer’s instructions (Promega, Madison, WI, USA). Cells
were counterstained with theD N A - b i n d i n gf l u o r e s c e n t
dye, Hoechst 33342 (Molecular Probes, Eugene, OR,
USA) at 1 μg/ml for 10 min at room temperature to
reveal nuclear morphology. Images were obtained using
a Zeiss 510 meta confocal microscope. The number of
apoptotic cells was expressed as the percentage of
TUNEL-positive cells of the total number of nuclei
determined by Hoechst staining.
Cell survival assay
Neuronal viability was detected by using a 2-(2-meth-
oxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophe-
nyl)-2H-tetrazolium monosodium salt (WST-8) assay
(Dojindo Molecular Technologies, Gaithersburg, ML,
USA). The cell survival rate was expressed as the viabi-
lity percentage of the vehicle-treated cells.
Caspase-9, caspase-8 and caspase-3 activities
The caspase-9, caspase-8 and caspase-3 activities in cell
lysates were determined using caspase-9, caspase-8 and
caspase-3 Colormetric Assay Kits (Chemicon, Rosemont,
IL). Approximately 50 μg of protein was incubated with
DEVD-pNA (for caspase-3; 50 μM), IETD-pNA (for cas-
pase-8; 50 μM) or LEHD-pNA (for caspase-9; 50 μM)
and 10 mM DTT at 37°C for 2 h. Substrate hydrolysis
was determined as absorbance change at 405 nm in a
microplate reader. Enzymatic activity was expressed in
arbitrary units (optical density, OD) per mg protein.
Western blot analysis
Whole cellular extracts and nuclear protein fractions
were prepared and protein concentration was deter-
mined by using Bradford protein assay (Bio-Rad, Her-
cules, CA, USA); 10-50 μg of protein was analyzed by
10% SDS-PAGE and transferred to nitrocellulose mem-
branes that were then blocked with 5% nonfat milk in
TBS (100 mM, Tris pH 8.0, 1.5 M of NaCl, 0.1% Tween
20) for 1 h. The membranes were incubated overnight
with primary antibodies, washed with TBS, and incu-
bated with a horseradish peroxidase-conjugated second-
ary antibody for 1 h. Immunoreactivity was detected by
using the ECL detection system (Thermo Scientific,
Rockford, IL, USA).
Akt kinase assay
We followed instructions in the Akt kinase assay kit
from Cell Signaling Technology (catalog # 9840). Cells
were washed with PBS and lysed in cell lysis buffer.
Twenty microliters of immobilized Akt primary antibody
bead slurry was added to 200 μl of whole-cell extract
(150 μg of protein) overnight at 4°C. After centrifuga-
tion, the supernatant was saved for b-actin detection by
western blot to confirm that the same amount of whole-
cell extract was used for the Akt kinase assay as
reported [41]. Immunoprecipitates were washed three
times with lysis buffer and twice with Akt kinase buffer.
Kinase assays were performed for 30 min at 30°C under
continuous agitation in kinase buffer containing 200 μM
ATP, 1 μg of GSK-3 fusion protein. Samples were
analyzed by western blot using phospho-GSK-3a/b
(Ser21/9) antibody.
Ad.
AktK179A and Ad.FKHRL-TM constructs
The kinase-inactive Akt
K179A [46] or a triple mutant of
FKHRL1 (FKHRL1-TM) [47] was cloned into a
GFP-containing adenoviral vector using AdEasy ™XL
system (Stratagene, Cedar Creek, TX, USA). The adeno-
viral product containing Akt
K179A or FKHRL1-TM
was amplified in HEK 293A cells from American Type
Culture Collection (ATCC, Manassas, VA, USA) and
purified using ViraKit ™(Virapur, San Diego, CA, USA).
Cortical neurons were transduced with adenoviral con-
structs (200 MOI) 24 h before studies. The transduction
efficiency was determined by GFP signal and western
blot analysis.
Tyro3 tyrosine phosphorylation
Neurons were lysed with Radio ImmunoPreciptation
Assay (RIPA) Buffer (50 mM Tris, pH 8.0, 150 mM
NaCI, 0.1% SDS, 1.0% NP-40, 0.5% sodium deoxycho-
late and Roche protease inhibitor cocktail) and incu-
bated with a rabbit anti-phospho-tyrosine antibody
(Abcam, Cambridge, MA) or a control non-immune
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then immunoprecipitated using a protein G immuno-
precipitation kit (Roche) followed by SDS-PAGE separa-
tion and transfer onto nitrocellulose membranes
(Millipore Corp). After blocking non-specific sites with
5% milk, the membranes were incubated with a rat
monoclonal anti-mouse Tyro3 antibody (R&D Systems)
or a rabbit anti-mouse vascular endothelial growth fac-
tor receptor 2 (VEGFR2) antibody (Millipore, Billerica,
MA) for a loading control. Following incubation with an
HRP-conjugated donkey-anti goat secondary antibody
(Santa Cruz Biotechnology), the immunoreactivity was
detected using the SuperSignal
® West Pico chemilumi-
nescent substrate (Thermo Scientific). Cells were trea-
ted with mouse PS for 2 h.
Statistical analysis
We used S-plus 7.0 for statistical calculations. Data are
presented as mean ± SEM. Student’s t-test and one-way
analysis of variance (ANOVA) followed by Tukey’sp o s t -
hot test were used to determine statistically significant dif-
ferences. P < 0.05 was considered statistically significant.
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